ABSTRACT
BACKGROUND: Breast cancer is the cancer with the highest incidence and mortality worldwide. Its treatment is multidisciplinary with surgery, systemic therapy, and radiotherapy. In Colombia, according to Globocan 2018, there is an age-standardized incidence rate of 44 per 100,000 women. Radiotherapy improves local and regional control in patients with breast cancer, and it could even improve relapse-free survival and overall survival in patients with nodal disease. The toxicity of this treatment in most cases is mild and transient, but in a low percentage of patients, radiotherapy-induced tumors may develop. CASE PRESENTATION: Seven Colombian patients treated for breast cancer at our institution developed radiotherapy-induced tumors between 2008 and 2018. The median age was 54.4 (range 35-72) years. Six patients had locally advanced tumors at the time breast cancer was diagnosed, and all of them received neoadjuvant or adjuvant chemotherapy and radiotherapy. The radiotherapy-induced tumors were five sarcomas, one of which was a well-differentiated angiosarcomatous vascular lesion with negative c-Myc (benign lesion), and the remaining patient had basal cell carcinoma associated with radiotherapy. CONCLUSIONS: Sarcomas are the most common radiotherapy-induced tumors after breast cancer treatment. These are rare, aggressive tumors and represent between 0.5% and 5.5% of all sarcomas. Basal cell carcinoma has also been associated with breast cancer treatment. The management is individualized and multimodal, including surgical resection and chemotherapy. Different studies have shown that radiation therapy is a risk factor for the development of soft tissue tumors.
Subject(s)
Breast Neoplasms , Neoplasm Recurrence, Local , Adult , Aged , Breast Neoplasms/pathology , Chemotherapy, Adjuvant , Colombia/epidemiology , Combined Modality Therapy , Female , Humans , Middle Aged , Neoadjuvant Therapy , Neoplasm Staging , Radiotherapy, Adjuvant/adverse effectsABSTRACT
El mesotelioma peritoneal es una neoplasia que se origina en las células mesoteliales del peritoneo. Histórica-mente, la supervivencia de los pacientes con mesotelioma peritoneal maligno sin tratamiento, es menor de 12 meses y se considera una neoplasia resistente a la quimioterapia. La citorreducción quirúrgica y la quimioterapia regional administrada como quimioterapia hipertérmica intraperitoneal (Hyperthermic Intraperitoneal Chemothe-rapy, HIPEC) se asocia con mejor supervivencia a largo plazo.Se presenta el caso de un paciente con antecedentes de exposición al asbesto y con diagnóstico de mesotelioma peritoneal maligno de tipo epitelioide, que fue tratado con cirugía citorreductora más quimioterapia hipertérmica intraperitoneal en el Instituto Nacional de Cancerología con una supervivencia de un año libre de enfermedad
Peritoneal mesothelioma is originated at the mesothelial cells of the peritoneum. Historically the survival of patients with this disease is less than 12 months without treatment and it is considered a neoplasm resistant to chemotherapy. Citorreductive surgery with hiperthermic intraperitoneal chemotherapy (HIPEC) is associated with an increased long-term survival. Here we present the case of a patient who had a past history of asbestos exposure and who was diagnosed with peritoneal mesothelioma of the epithelioid subtype. The patient was treated with cytoreductive surgery and HIPEC at the Instituto Nacional de Cancerología (Bogotá, Colombia) and has had a 12 month disease free survival
Subject(s)
Humans , Mesothelioma , Chemotherapy, Cancer, Regional Perfusion , Cytoreduction Surgical Procedures , Hyperthermia, InducedABSTRACT
Antecedentes: La cirugía gástrica cooperativa utliza vías simultáneas intraluminal peroral e intraperitoneal transabdominal para localizar y tratar, en tempo real, lesiones de dificil manejo con procedimientos convencionales. Su objetivo es resecar lesiones con técnicas videoasistidas, simultáneas, conservando tejido y funcionalidad, con los beneficios de la cirugía mínimamente invasiva. Objetivos: Describir nuestra experiencia en la realización de procedimientos cooperativos gástricos en el Instituto Nacional de Cancerología. Material y métodos: Revisión prospectiva de una base datos retrospectiva. Análisis descriptivo de pacientes en quienes se realizaron procedimientos gástricos cooperativos en el Instituto Nacional de Cancerología de Bogotá, Colombia, intervenidos entre octubre de 2012 y noviembre de 2016. Resultados: Se realizaron 16 procedimientos gástricos laparoendoscópicos: ocho de las 16 lesiones resecadas fueron subepiteliales, 4 intervenciones se indicaron para ampliación de márgenes posterior a resección endoscópica, 2 fueron lesiones epiteliales y 2 procedimientos se realizaron para control del sangrado con intención paliativa. Catorce procedimientos fueron de tpo exogástrico, 1 intragástrico y 1 transgástrico. El tempo quirúrgico promedio fue de 91 minutos, con pérdidas sanguíneas en promedio de 42 mL con bordes de resección negativos en todos los casos. El tempo promedio de hospitalización fue de 4 días. La supervivencia libre de enfermedad a 22 meses fue del 100%. Conclusiones: Los resultados de nuestro estudio muestran que la cirugía gástrica cooperativa es una técnica segura, factible, con tempos quirúrgicos aceptables y sangrados mínimos en pacientes con comorbilidades y sin ellas, conservando los principios oncológicos y de la cirugía mínimamente invasiva en el tratamiento de las neoplasias gástricas.
Background: cooperative gastric surgery uses simultaneous, intraluminal peroral and intraperitoneal trans-abdominal pathways to localize and treat, in real tme, dificult tumors with conventonal proce-dures. The aim is to resect lesions of diferent etology with video assited techniques, simultaneous, preserving tssue and functonality, with the benefts of minimally invasive surgery. Objective: the aim of our study was describe our experience in cooperative gastric procedures at the Natonal Cancer Institute in Bogotá, Colombia. Materials and methods: prospective review of a retrospective database. Descriptive analysis of pa-tents in whom cooperative gastric procedures were performed at the Natonal Cancer Institute of Bogotá, Colombia, between October 2012 and November 2016. Results: sixteen laparoscopic endoscopic cooperative procedures were performed; eight of 16 resec-ted tumors were subepithelial; four cases were done for resecton of previous positive margins, two epithelial lesions and two for bleeding and palliative control. Fourteen procedures were exogastric, 1 intragastric and 1 transgastric. The operative tme was 91 minutes, the average bleeding was 42 cc and negative margins were present in all cases. The mean hospital stay was 4 days. Conclusions: Our study shows that laparoscopic endoscopic cooperative surgery is a safe and feasible technique with acceptable operative tmes and minimal bleeding in patents with and without comorbidites, preserving the oncological and minimally invasive principles in the treatment of gastric neoplasms.
